Oral Estradiol Regret, Stopping, and Restarting: What Real Patients and the Evidence Actually Show

What the label says about stopping

The tablet label sets a review cycle: attempts to taper or discontinue should be made at 3-month to 6-month intervals, with reevaluation at the same interval to decide whether treatment is still necessary [1]. The label says administration should be cyclic (for example 3 weeks on, 1 week off), and gives a usual initial range for menopausal symptoms of 1 to 2 mg daily of estradiol, adjusted as necessary to control symptoms [1]. On 2025-11-10 FDA asked makers of menopausal hormone therapy to remove the recommendation to use the lowest effective dose for the shortest time, along with boxed-warning language on cardiovascular disease, breast cancer and probable dementia [5].

After the last tablet

The label describes a two-year randomized, double-blind, placebo-controlled dose-ranging study in which 0.5 mg estradiol daily for 23 of 28 days prevented vertebral bone mass loss in postmenopausal women, and states that when estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period [1]. For women with a uterus who take unopposed estrogen, the label says endometrial cancer risk depends on duration and dose, is greatest after 5 to 10 years or more, and persists for 8 to over 15 years after estrogen therapy is discontinued [1].

Who the label says should not use estrogens

The tablet label's contraindications are undiagnosed abnormal genital bleeding; known, suspected or past breast cancer except in appropriately selected patients treated for metastatic disease; known or suspected estrogen-dependent neoplasia; active DVT or PE, or a history of either; active or recent stroke or heart attack; liver dysfunction or disease; hypersensitivity to ingredients; and known or suspected pregnancy [1]. The 2 mg tablet contains tartrazine (FD&C Yellow No. 5) [1]. The Climara patch label adds protein C, protein S or antithrombin deficiency and other thrombophilic disorders [4]; that is the patch label, not the tablet's.

The boxed warning on the tablet label

FDA's 2025 request kept the endometrial cancer boxed warning on systemic estrogen-alone products while asking makers to remove the cardiovascular, breast cancer and probable dementia language [5]. The first six updated labels were approved on 2026-02-12 [7]. Oral estradiol tablets and estradiol patches are not on FDA's list of updated labels [6]; the tablet and Climara patch labels checked still carry the older, longer boxed warning [1][4].

Oral versus patch: clot data

The Climara label states that systemic availability of estradiol after transdermal use is about 20 times higher than after oral use because there is no first-pass metabolism [4]. In ESTHER, an observational French case-control study of 271 women with a first idiopathic clot and 610 matched controls, the adjusted odds ratio for VTE was 4.2 (95% CI 1.5 to 11.6) for current oral estrogen and 0.9 (0.4 to 2.1) for transdermal [2]. A meta-analysis of eight observational studies and nine randomized trials reported pooled observational odds ratios of 2.5 (1.9 to 3.4) for oral and 1.2 (0.9 to 1.7) for transdermal [3]. These are observational comparisons, not randomized proof that patches are free of clot risk; the Climara label lists active or past DVT or PE as a contraindication [4].